Utah Medical Products posts strong margins and cash; revenue pressured by OEM and OUS weakness

Utah Medical Products, Inc. (NASDAQ: UTMD) - Quick read

Summary: UTMD delivered solid profitability and cash generation in 2Q/1H 2025 but saw revenue and gross‑profit pressure primarily from reduced OEM (PendoTECH) demand and weaker international sales. The company remains debt‑free with an active buyback/dividend program.

Key facts & figures (as reported)
* Sales, net - 2Q 2025: $9,953 vs 2Q 2024: $10,400; 1H 2025: $19,663 vs 1H 2024: $21,740
* Cost of goods sold - 2Q 2025: $4,358; 1H 2025: $8,530
* Gross profit - 2Q 2025: $5,595 vs $6,253; 1H 2025: $11,133 vs $13,018
* Gross profit margin - 2Q 2025: 56.2% (2Q 2024: 60.1%); 1H 2025: 56.6% (1H 2024: 59.9%)
* Operating income - 2Q 2025: $3,196 vs $3,438; Operating margin 2Q 2025: 32.1% (2Q 2024: 33.1%)
* Net income - 2Q 2025: $3,048 vs $3,453; 1H 2025: $6,089 vs $7,409 (all amounts in thousands)
* Earnings per share (diluted) - 2Q 2025: $0.94 vs $0.98; 1H 2025: $1.86 vs $2.07
* Adjusted consolidated EBITDA - 2Q 2025: $4,671; 1H 2025: $9,323; trailing‑12‑month EBITDA: $18,686
* Cash & investments - $82,179 (as of June 30, 2025) (reporting basis: in thousands)
* Total assets / total liabilities - Total assets: $120,802; Total liabilities: $3,269 (June 30, 2025, in thousands)
* Inventories - $8,233 (June 30, 2025)
* Goodwill / intangible assets - Goodwill: $14,193; Other intangible assets, net: $1,977 (June 30, 2025)
* Shares outstanding - 3,205,723 (as of Aug 11, 2025); diluted shares used in EPS calc: 3,246 (2Q 2025)
* Share repurchases - 1H 2025: 119,255 shares repurchased for $6,709; additional 10,178 repurchased after 6/30 through 8/11 for $567 (avg $55.67)
* Dividends - 1H 2025 cash dividends paid: $2,018
* Current ratio (reported) - 41.9 (June 30, 2025); company reports no debt

Positive takeaways
* Strong balance sheet and cash position: $82,179 (in thousands) and no debt - provides capital flexibility.
* High operating profitability: operating margin ~32% in 2Q 2025 despite lower sales.
* Consistent cash generation: net cash from operations $7,337 (1H 2025) and adjusted EBITDA remains robust (TTM $18,686).
* Capital returns intact: ongoing dividends ($2,018 in 1H) and active buybacks that materially reduced share count - helping EPS resilience.
* Management guidance appears disciplined: expects full‑year EBITDA target ($17-$18M) achievable; Femcare IIA amortization finishes in 1Q 2026 (reduces future non‑cash expense).

Negative / risk points
* Revenue decline: consolidated sales down 4.3% in 2Q and 9.6% for 1H - driven largely by sharply lower PendoTECH OEM sales (71% of 2Q decline; 86% of 1H decline).
* Margin compression: gross margin fell to 56.2% in 2Q from 60.1% a year earlier, blamed on unfavorable product mix and weaker Ireland operations.
* International weakness: OUS sales dropped (2Q OUS: $4,088 vs $4,569); constant‑currency OUS sales fell materially (21.4% lower in 2Q).
* Lower non‑operating income: interest income declined (lower rates) - reduced net non‑operating income (2Q 2025: $640 vs $773).
* Higher effective tax rate: provision rate rose (2Q 2025: 20.5% vs 18.0%), aggravating Net Income decline.
* Exposure to external risks: potential reciprocal tariffs and distributor delays could further hit OUS shipments; Filshie product‑liability litigation remains in discovery (company does not expect material impact but it's ongoing).

Operational / segment notes
* Domestic vs OUS - 2Q 2025 domestic sales: $5,865; OUS: $4,088. Domestic held steady while OUS weakness drove much of the top‑line decline.
* Product mix - 2Q 2025 by category: Gynecology/Electrosurgery/Urology $4,807; Neonatal $2,102; Blood Pressure Monitoring & Accessories $2,019; Obstetrics $1,025.
* Gross profit issues localized to Ireland - unfavorable product mix, lower absorption of fixed MOH and higher raw materials affected Ireland margins.

What to watch next
* PendoTECH volumes - management expects ~ $2M lower annual sales to this OEM in 2025 vs 2024; monitor 2H shipments and any recovery.
* OUS distributor orders and tariff developments - delays or tariffs could push sales into 2026 and further pressure Ireland margin absorption.
* Cash deployment - continued buybacks/dividends vs opportunistic M&A; repurchase cadence affects shares outstanding and EPS.
* Litigation developments around Filshie clip product liability - currently in discovery.

Bottom line: UTMD remains a cash‑rich, high‑margin medical device company executing disciplined capital returns. The near‑term story is top‑line pressure from lost OEM business and softer international demand that trimmed gross profit and net income; however, operating margins, strong cash, no debt and ongoing buybacks/dividends keep EPS and shareholder returns supported.